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Abstract The use of contrast media for cardiac
imaging becomes increasing as the widespread of
cardiac CT and cardiac MR. A radiologist needs to
carefully consider the indication and the injection
protocol of contrast media to be used as well as the
possibility of adverse effect. There are several
guidelines for contrast media in western countries.
However, these are focusing the adverse effect of
contrast media. The Asian Society of Cardiovascular
Imaging, the only society dedicated to cardiovascular
imaging in Asia, formed a Working Group and
created a guideline, which summarizes the integrated
knowledge of contrast media for cardiac imaging. In
cardiac imaging, coronary artery evaluation is feasi-
ble by non-contrast MR angiography, which can be
an alternative examination in high risk patients for
the use of iodine contrast media. Furthermore, the
body habitus of Asian patients is usually smaller than
that of their western counterparts. This necessitates
modiﬁcations in the injection protocol and in the
formula for calculation of estimated glomerular
ﬁltration rate. This guideline provided fundamental
information for the use of contrast media for Asian
patients in cardiac imaging.
Keywords Contrast media  Adverse effect 
Injection protocol
1 Introduction
As the use of contrast media in cardiac imaging is
becoming more common, a radiologist needs to
carefully consider the indication and the injection
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possibility of adverse effect. There are several
guidelines focusing the adverse effect of contrast
media [1, 2]. However, there is no guideline, which
summarizes the integrated knowledge of contrast
material for cardiac imaging, especially for patients
of Asian origin. In cardiac imaging, coronary artery
evaluation is feasible by non-contrast MR angiogra-
phy, which can be an alternative examination in high
risk patients for the use of iodine contrast media.
Furthermore, the body habitus of Asian patients is
usually smaller than that of their western counter-
parts. This necessitates modiﬁcations in the injection
protocol and in the formula for calculation of
estimated glomerular ﬁltration rate (eGFR) [3, 4].
The major purpose of this manual is to provide
fundamental information for the use of contrast
media for Asian patients in cardiac imaging.
For the usage of contrast material, the basic
knowledge for contrast material injection is very
important to obtain optimal contrast images. The
knowledge for adverse reaction is inevitable for the
safe patient care. Among several adverse reactions,
contrast induced nephropathy (CIN) is almost speciﬁc
to iodinated contrast media, while nephrogenic sys-
temic ﬁbrosis (NSF) is speciﬁc to gadolinium contrast
media. On the other hands, adverse reactions other
than CIN and NSF is similar in both iodinated and
gadolinium contrast material. Thus, this guideline
consists of four chapters; (1) general rule for contrast
material injection, (2) adverse reaction of iodinated
and gadolinium contrast material, (3) contrast induced
nephropathy and (4) nephrogenic systemic ﬁbrosis.
2 General rule for contrast material injection
2.1 Computed tomography contrast material
Contrast enhancement in a given patient is determined
by3factors:contrastmaterialﬂowrate(ml/s),contrast
material volume (ml) and contrast material iodine
concentration (mg/ml) [5]. The overall contrast vol-
umeiscalculatedastheinjectionratemultipliedbythe
injection duration. Warming of contrast agent prior to
injection decreases viscosity and allows higher injec-
tion rates at lower injection pressures.
Accurate timing of the scan with respect to the
arrival of the intravenous (IV) contrast in the target
structures is necessary. Thus, the usage of either bolus
tracking or a test bolus protocol is recommended.
2.1.1 Coronary CT Angiography
• The injection ﬂow rate mainly determines the
enhancement (fast dynamic peak). The contrast
material volume also affects the enhancement
[6, 7].
• Optimal images require high intraarterial opaci-
ﬁcation of more than 250 Hounsﬁeld units (HU)
[8]. Higher intracoronary attenuation value will
improve the diagnostic accuracy of coronary
artery stenosis [9, 10].
• High iodine concentration contrast agents are
preferred to achieve greater contrast-to-noise
ratios [11, 12].
• The injection duration should be as long as or
slightly longer than the estimated scan duration.
For very short scans, the injection duration should
be at least 10 s [5].
• A biphasic injection protocol using dual-head
pumps is preferable [13, 14]. It consists of a ﬁrst
injection of contrast at a rate of 3–6 ml (volume
depends on scan length) and a second injection of
approximately 20–40 ml of saline at the same
injection rate.
• A body weight tailored injection protocol is
recommended to decrease the total contrast
material volume in Asian patients. The use of
0.7 ml/kg of contrast material injected at a ﬁxed
duration of 10 s followed by 20 ml of saline is
feasible [15, 16].
2.1.2 Other protocols
• In CT angiography (CTA) protocols, the right
heart typically appears washed out. In some
clinical settings, it may be desirable to have some
opaciﬁcation of the right heart.
• For the right heart opaciﬁcation, the saline ﬂush
may be replaced by a mixture of contrast and
saline, or a triphasic injection protocol may be
used [17–19].
• Triphasic protocols consist of an initial high ﬂow
rate contrast injection (3–6 ml/s), followed by a
second injection of either a mixture of contrast
204 Int J Cardiovasc Imaging (2010) 26:203–212
123and saline (3–6 ml/s) or a contrast injection at
lower injection rate (e.g., 2 ml/s), followed by a
third injection of a smaller volume of saline.
• Regarding the protocol for the evaluation of
delayed enhancement, further studies are
required.
2.2 Magnetic resonance contrast material
Gadolinium based contrast media (GBCM) shorten
T1 relaxation times and thus lead to higher signal
intensity on T1-weighted images. Although ﬁrst-pass
kinetics and late distribution of GBCM are similar to
those of iodinated contrast materials for CT; there are
two distinct characteristics in GBCM compared to
iodinated contrast materials. First, the signal intensi-
ties are not proportional to GBCM concentration due
to substantial signal loss caused by T2-shortening
effect at high concentrations of GBCM. Therefore,
the concentration of GBCM in the blood pool or
myocardium cannot be calculated directly from the
signal intensity on MRI [20]. Second, due to the
much smaller contrast volume required for ﬁrst-pass
imaging, improving effect of high injection rate on
bolus proﬁle is limited for MRI compared to CT [21].
For example, when you administer a single dose of
GBCM to a patient with 50 kg body weight (i.e.
10 ml), increasing injection rate from 4 to 5 ml/s
shortens the injection duration only slightly (i.e.
0.5 s).
The injection protocol for myocardial perfusion
MRI is usually used as a dose of 0.05–0.1 mmol/kg
with injection rate of 3–7 ml/s, followed by at least
30 ml saline ﬂush (5–7 ml/s). For delayed gadolin-
ium enhancement MRI, a total dose of 0.1–0.2 mmol/
kg is administered.
3 Adverse effects of iodinated and gadolinium
contrast medium
3.1 Patient selections and preparation strategies
Before the administration of contrast media, the
referring physician and the radiologist should con-
sider the following issues: (1) Assessment of patient
risk versus potential beneﬁt of the contrast-assisted
examination. (2) Imaging alternatives that would
provide the same or better diagnostic information.
(3) Prevention of adverse events.
3.1.1 Risk factors for adverse intravenous contrast
material reactions
• The history obtained should focus on identiﬁca-
tion of factors that may indicate either a contra-
indication to contrast media use or an increased
likelihood of a reaction.
• Severe, life-threatening reactions, although rare,
can occur in the absence of any speciﬁc risk
factors with any type of media [1].
• Risk factors for adverse reactions to contrast
media are summarized in Table 1.
• In pregnant patients, it is unclear how iodinated or
gadolinium contrast agents will affect the fetus,
these agents should be administered only with
extreme caution. Free iodine in radiographic
contrast medium given to the mother has the
potential to depress fetal/neonatal thyroid func-
tion. Neonatal thyroid function should be checked
during the 1st week if iodinated contrast media
have been given during pregnancy. No effect on
the fetus has been seen after gadolinium contrast
media [22].
• In lactating patients, breast feeding may continue
normally when iodinated or gadolinium agents
are given to the mother [22].
Table 1 Risk factors for adverse intravenous contrast material
reactions
Iodinated contrast media Gadolinium contrast media
Patients at increased risk of reaction
a
Previous moderate or severe
acute reaction to iodine
contrast agent
Previous moderate or severe











a A prior major anaphylactic response to one or more allergens
b Especially when present in those who live in iodine-deﬁcient
areas
c Especially in case of high osmolality contrast media
(HOCM) administration
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1233.1.2 Preparation strategies
• For patients at increased risk of reaction, consider
an alternative test not requiring the agent. For the
evaluation of coronary artery, non-contrast MR
angiography can be an alternative examination
[23].
• There is no concrete clinical evidence on the
effectiveness of use of premedication in patients
undergoing contrast enhanced CT or MRI
examinations.
• However, the premedication is preferable in
patients at higher risk for an acute allergic-like
reaction.
• If the radiologists does intend to use premedica-
tion then a useful option can be prednisolone
30 mg orally, given 12–2 h before the contrast
medium [2].
• Preliminary intradermal skin testing with contrast
agents is not predictive of adverse reactions, may
itself be dangerous, and is not recommended
[24, 25].
3.2 At the time of examination
A general category that deserves attention is emo-
tional state. There is anecdotal evidence that severe
adverse effects to contrast media or to procedures can
be mitigated at least in part by reducing anxiety.
It may be useful, therefore, to determine whether a
patient is particularly anxious and it is important to
reassure and calm that patient before contrast injec-
tion [26].
3.2.1 To reduce the risk of adverse reactions
• Some of the strategies to avoid contrast media
induced adverse events are listed in Table 2.
3.2.2 Extravasation
Frequencies
• The reported incidence of IV contrast media
extravasation related to power injection for CT
has ranged from 0.1% to 0.9% (1/1,000 patients to
1/106 patients) [27].
• The frequency of extravasation is not related to
the injection ﬂow rate [28].
Risk factors
• Inappropriate injection site (small vessels),
• High volume of contrast media or high osmolar
contrast media.
• Use of power injectors.
Type of injuries
• Most injuries are minor.
• In severe cases, ulceration, soft tissue necrosis or
compartment syndrome may be observed.
• A compartment syndrome is more likely to occur
after extravasation of larger volumes of contrast
media [29]; however, it also has been observed
after extravasation of relatively small volumes,
especially when this occurs in less capacious
areas (such as over the ventral or dorsal surfaces
of the wrist).
To reduce the risk
• Use appropriate sized plastic cannula placed in a
suitable vein to handle the ﬂow rate.
• A test injection with normal saline.
• Use non-ionic iodinated contrast medium as far as
possible.
Treatment
• Conservative management (limb elevation, use of
ice packs) is adequate in most cases.
• Close clinical follow-up for several hours is
essential for all patients in whom extravasations
occur, since the severity and prognosis of a
contrast medium extravasation injury are difﬁcult
to determine on initial evaluation of the affected
site.






Use a non-ionic contrast
medium
Use a different gadolinium
contrast agent for previous
reactors to contrast medium Use a different iodinated agent
for previous reactors to
contrast medium
206 Int J Cardiovasc Imaging (2010) 26:203–212
123• An immediate surgical consultation is indicated
for any patient in whom one or more of the
following signs or symptoms develops: progres-
sive swelling or pain, altered tissue perfusion as
evidenced by decreased capillary reﬁll at any time
after the extravasation has occurred, change in
sensation in the affected limb, and skin ulceration
or blistering.
3.3 Type of adverse reactions
Adverse reactions are classiﬁed into acute and
delayed reactions [2]. Acute reactions are those that
occur up to 1 h after the administration of CM. The
majority of the delayed reactions occur between 1
and 72 h after the administration of contrast media.
Subsequently occurring reactions are rare; the max-
imum interval is 7 days [2].
3.3.1 Acute adverse reaction
• The classiﬁcation of severity of reactions to
contrast media has been shown in Table 3.
• The majority of adverse side effects are mild non-
life-threatening events that require only observa-
tion and supportive treatment.
• Severe adverse side effects, however, may have a
mild or moderate prodrome. Nearly all life-
threatening reactions occur immediately or within
the ﬁrst 3 h after contrast media injection [30].
• Prediction of occurrence or severity is impossible,
although there are some known risk factors, and
anticipation and vigilance are critical [31].
• Mild reactions do not require treatment, but, as
noted, they may presage or evolve into a more
severe reaction. Any patient with any reaction
should, therefore, be observed for 20–30 min, or
as necessary, to ensure clinical stability and
recovery.
• Moderate adverse events, by deﬁnition, are not
immediately life-threatening (although they may
progress to be so) but often require treatment.
• Severe adverse events are potentially or immedi-
ately life-threatening.
• Historically, adverse effects have occurred in
5–15% of all patients who receive ionic, high-
osmolality contrast media (HOCM) [32]. One
study in Asia reported the frequency of adverse
effects was 12.66% with HOCM [33].
• Use of low-osmolality ionic nonionic contrast
media (LOCM) is associated with an overall
incidence of adverse events of 0.2–0.7% [34, 35].
In Asia, this is reported to be 3.13% [33].
• Serious contrast reactions are rare and have
occurred in 1 or 2 per 1,000 (0.1–0.2%) intravas-
cular injections of HOCM and in 1 or 2 per
10,000 (0.01–0.02%) IV injections of LOCM [1].
In a report from Asia, this frequency was 0.22%
of intravascular injections of ionic and 0.04% of
non-ionic IV injections [33].
• The adverse event rate for gadolinium based
contrast agents can range from 0.5 to 2.5% [36–
38].
• The management for acute adverse reactions is
the same with generalized anaphylactoid reaction.
This is summarized in Table 4.
• b-blockers may impair the response to treatment
of bronchospasm induced by contrast medium.
Table 3 Classiﬁcation of severity of reactions to contrast
media
Minor Moderate Severe
Nausea Faintness Hypotensive shock
Vomiting (Limited) Vomiting (Severe) Pulmonary edema
Pruritis Urticaria (Profound) Respiratory arrest
Diaphoresis Facial edema Cardiac arrest
Laryngeal edema Convulsions
Bronchospasm
Table 4 Management plan for contrast medium induced acute
adverse reaction
1. Call for resuscitation team
2. Suction airway as needed
3. Elevate patient’s legs if hypotensive
4. Oxygen by mask (6–10 l/min)
5. Intramuscular adrenaline (1:1,000), 0.5 ml (0.5 mg) in
adults. Repeat as needed. In pediatric patients 0.01 mg/kg
to 0.3 mg (max. dose)
6. Intravenous ﬂuids (e.g. normal saline, lactated Ringer’s)
7. H1-blocker e.g. diphenhydramine 25–50 mg
intravenously
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• An adverse reaction which occurs 1 h to 1 week
after contrast medium injection.
• The incidence of delayed adverse cutaneous
reactions has been reported to range from 0.5 to
2% [39].
• The main types of delayed reactions are given in
Table 5.
• Relatively common symptoms are nausea, vom-
iting, drowsiness, headache, and pruritus without
urticaria, all of which are self-limited and many
of which are self limiting and do not require any
therapy [39].
• Skin reactions are true late adverse reactions.
They are usually mild to moderate and self
limiting. Delayed cutaneous reactions are not,
however, associated with other acute adverse
events such as bronchospasm or laryngeal edema.
• The management of late adverse reactions is
identical to that of other drug induced skin
reactions.
• Delayed cardiopulmonary arrest has also been
reported, but this and other severe systemic
reactions are probably related to etiologies other
than the contrast media.
• Currently, very late reactions to gadolinium
media in the form of nephrogenic systemic
ﬁbrosis (NSF) are a major concern, and are dealt
with in detail in chapter D.
4 Contrast-induced nephropathy (iodinated
contrast medum)
Contrast medium nephrotoxicity (renal adverse reac-
tions) is mostly associated with iodinated contrast
media. The risk of nephrotoxicity is very low when
gadolinium contrast media are used in approved
doses.
The risk of nephrotoxicity is related to the degree
of pre-existing renal disease and hydration. Clinically
signiﬁcant nephrotoxicity after administration of
iodinated contrast media is highly unusual in patients
with normal renal function. There is no standard
deﬁnition for reporting contrast-induced nephrotoxi-
city (CIN). Deﬁnitions used have included percent
change in the baseline serum creatinine (e.g., a
20–50% rise in serum creatinine) and absolute
elevation from baseline (0.5–2.0 mg/dl) [40, 41].
The clinical course of CIN depends on baseline
renal function, coexisting risk factors, degree of
hydration, and other factors. Serum creatinine usually
begins to rise within the ﬁrst 24 h following IV
contrast media administration, peaks within 96 h
(4 days), and usually returns to baseline within
7–10 days [40]. It is unusual for patients to develop
permanent renal failure, and this usually occurs in the
setting of multiple risk factors.
4.1 Risk factors for adverse intravenous contrast
medium induced nephropathy
• The major risk factors for CIN is given in
Table 6.
• Serum creatinine values should be measured
within 7 days of contrast media administration.
• There is no universally agreed upon threshold of
serum creatinine elevation (or degree of renal
Table 5 Characteristics of contrast medium induced delayed
adverse reactions
Iodinated contrast media Gadolinium contrast media
Late adverse reactions
Mainly skin rashes None described
Very late adverse reactions
Thyrotoxicosis Nephrogenic systemic ﬁbrosis
(Patients with untreated Graves’ disease)
Table 6 Risk factors for contrast medium induced nephropa-
thy
Patient related
Pre-existing renal insufﬁciency (serum creatinine
level[1.5 mg/dl; Especially, patients with eGFR








Large doses of contrast medium
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123dysfunction) beyond which iodinated contrast
media should not be administered.
• Serum creatinine has limitations as an accurate
measure of renal function because it is inﬂuenced
greatly by the patient’s gender, muscle mass,
nutritional status, and age.
• Direct measurement of GFR with insulin or a
similar clearance marker would be preferable,
however, generally impractical.
• One alternative is to use a formula to calculate
creatinine clearance, (estimated GFR or eGFR)
based on age, gender, body weight, and serum
creatinine (e.g., Cockcroft-Gault formula or Mod-
iﬁcation of Diet in Renal Disease [MDRD]
formula) [42, 43].
• However, these equations are less accurate for
Asians, with greater bias at estimated GFR
(eGFR) less than 60 ml/min/1.73 m
2 [3]. This
difference would be accounted for by the differ-
ence in muscle mass. African-American people
probably have a greater muscle mass than Asian.
Interestingly, the correction coefﬁcients for the
modiﬁcation of the MDRD Study equation were
considerably different even among patients of
Asian origin. For example, the correction coefﬁ-
cient for patients of Chinese origin was 1.233 [4]
and that for patients of Japanese origin 0.808 [3].
• The establishment of GFR-estimating formulae
speciﬁc for patients of different race is required.
For example, in Japan, new formula is recom-
mended as follows; eGFR (ml/min/1.73 m
2) =




• Metformin is excreted unchanged in the urine. In
the presence of renal failure, either pre-existing or
induced by iodinated contrast medium, metfor-
min may accumulate in sufﬁcient amounts to
cause lactic acidosis. Depending on serum creat-
inine level, metformin will have to be stopped
either before or at the time of contrast medium
administration.
4.2 Prevention or amelioration
• Consider an alternative imaging method not using
iodinated contrast media. For the evaluation of
coronary artery, non-contrast MR angiography
can be an alternative examination [23].
• Stop nephrotoxic drugs, mannitol and loop diuret-
ics at least 24 h before [44].
• Start hydration. A suitable intravenous regime is
100 ml/h of normal saline beginning 12 h before
and continuing 12 h after examinations. In hot
climates the volume should be increased [45].
• Stop metformin from the time of contrast medium
administration or 48 h. Only restart metformin if
serum creatinine remains normal or unchanged
48 h after contrast medium.
• The efﬁcacy of N-acetylcysteine (Mucomyst) or
sodium bicarbonate to reduce the incidence of
CIN is controversial [46–48].
4.3 At the time of examination
• Use low or iso-osmolar contrast media.
• Use the lowest dose of contrast medium consis-
tent with a diagnostic result.
• Continue hydration for at least 6 h [49].
• In patients suffering from end-stage renal disease,
there is no need for urgent dialysis [50].
• Correlation of time of the contrast medium
injection with the hemodialysis session in dialysis
patients is unnecessary [50].
5 Nephrogenic systemic ﬁbrosis (gadolinium
contrast media)
Nephrogenic systemic ﬁbrosis (NSF) is recently
reported adverse effect speciﬁc to gadolinium con-
trast media. Fewer cases of NSF have been reported
in Asia, as compared to the US or Europe [51]. NSF
is a severe, usually progressive, potentially fatal,
systemic ﬁbrotic disease, affecting the dermis, sub-
cutaneous fasciae and striated muscles. In 2006
several groups noted a strong association between
gadolinium-based contrast media (GBCM) adminis-
tration and the disease [52]. In many cases, affected
patients had been injected with more than one type of
GBCM prior to symptoms onset. However, it must be
emphasized that the frequency with which NSF has
been associated with different GBCM may also have
been affected if the agents were used at higher doses
compared to what is recommended in their package
inserts. It is advisable to use the GBCM agents within
their prescribed dosages and not to overdose the
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123patient. Risk factors for nephrogenic systemic ﬁbrosis
are given in Table 7.
The etiology of NSF is still unknown but is
thought to be multifactorial. The prevailing theory
regarding gadolinium and NSF is that gadolinium
(Gd
3?) ions are released from the Gd-chelate com-
plex of MRI contrast agents and accumulate in tissues
such as skin, thereby initiating what some have
described as a ‘‘toxic’’ reaction. The precise patho-
mechanism is not yet known [53].
It is estimated that patients with eGFR\30 ml/
min/1.73 m
2 have a 1–7% chance of developing NSF
after exposure to GBCM [52, 54]. All patients should
be questioned for a history of renal disease. The
measurement of an eGFR within 6 weeks of the
GBCM study is recommended in patients with renal
disease in anyone over 60 years of age, or in patients
with hypertension, diabetes mellitus.
5.1 Preparation strategies
• In patients with already being dialyzed.
Non-contrast MR angiography is recommended for
the evaluation of coronary artery. The use of CT
angiography is also possible. If a contrast-enhanced
MRI examination must be performed such as for the
evaluation of perfusion or delayed enhancement,
avoidance of the use of those GBCM that have been
most frequently associated with NSF [gadodiamide
(Omniscan
 ), gadopentetate dimeglumine (Magne-
vist
 ) and gadoversetadmide (OptiMARK
 ]) is rec-
ommended. Also, use of the lowest possible dose
needed to obtain a diagnostic study is suggested.
GBCM-enhanced MRI exams is recommended to
be performed shortly before dialysis, as prompt
post-procedural dialysis may reduce the likelihood
that NSF will develop, although this has not been
proved deﬁnitively to date [55].
• In patients with eGFR\30 ml/min/1.73 m
2, who
are not on chronic dialysis.
It is recommended that any contrast media admin-
istration be avoided if at all possible. If MRI contrast
media administration is absolutely essential, judicious
use of the lowest possible doses of selected GBCM
(avoidance of the use of those GBCM that have been
most frequently associated with NSF) is probably
safest [55].
To the best of our knowledge this is the ﬁrst
comprehensive guide on use of contrast media
amongst Asians for cardiac imaging. In summary
this manual provides basic information for the use of
contrast media for Asian patients in cardiac imaging.
In addition to general principles of contrast material
injection we have also discussed associated adverse
events like contrast induced nephropathy and neph-
rogenic systemic ﬁbrosis.
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